Report Detail
Sialorrhea- Market Insights, Epidemiology and Market Forecast-2028
- RnM3869827 |
- 24 January, 2020 |
- Global |
- 149 Pages |
- DelveInsight |
- Other
DelveInsight’s Sialorrhea- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Sialorrhea in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.
The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Sialorrhea from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.
Geography Covered
• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan
Study Period: 2017-2028
Sialorrhea- Disease Understanding and Treatment Algorithm
Sialorrhea, also known as hypersalivation or ptyalism, is excessive salivation associated with neurological disorders or localized anatomical abnormalities in the oral cavity. Sialorrhea can be classified as anterior and posterior; both can occur separately or simultaneously. Posterior sialorrhea is the flowing of saliva from the tongue to the pharynx. Anterior sialorrhea results in salivary incontinence or involuntary spillage of saliva over the lower lip, known as drooling. The underlying etiology is the excessive production of saliva or inability to retain saliva within the mouth due to reduced neuromuscular control of the tongue, oral tissues, and impairment in the swallowing mechanism, all of which are necessary to move saliva from the oral cavity to the oropharynx and beyond.
The DelveInsight Sialorrhea market report gives the thorough understanding of the Sialorrhea by including details such as disease definition, classification, symptoms, etiology, associated risk factors, pathophysiology, clinical features and diagnostic trends. It also provides treatment algorithms and management approaches for Sialorrhea in the US, Europe and Japan.
Sialorrhea Epidemiology
The Sialorrhea epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Epidemiology of Sialorrhea Associated Etiologies, Occurrence of Sialorrhea, Occurrence of Chronic Sialorrhea) scenario of Sialorrhea in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.
According to DelveInsight estimate, there were 2,484,780 cases of Sialorrhea in 7MM in 2017.Sialorrhea Drug Chapters
This segment of the Sialorrhea report encloses the detailed analysis of marketed drugs late stage (Phase-III and Phase-II) pipeline drugs along with other clinical candidates. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval, advantages and disadvantages of each included drug and the latest news and press releases.
Anticholinergics and botulinum dominate the Sialorrhea treatment landscape and therefore generate revenue. Most medications that are used to reduce saliva production have anticholinergic action at the muscarinic receptor. However, the lack of selectivity means that systemic side effects with these medications can be troublesome and impact their use. Botulinum Toxins and are increasingly being recognized as a safe and effective alternative to systemic medications for the reduction of saliva, without many of the side-effects.
Sialorrhea Market Outlook
The Sialorrhea market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.
This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the market of Sialorrhea in 7MM was found to be USD 1073.62 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Sialorrhea, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
Sialorrhea Drugs Uptake
This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Sialorrhea Report Insights
• Patient Population
• Therapeutic Approaches
• Pipeline Analysis
• Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies
Sialorrhea Report Key Strengths
• 10 Years Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake
Sialorrhea Report Assessment
• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers
Key Benefits
• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Sialorrhea market
• Organize sales and marketing efforts by identifying the best opportunities for Sialorrhea market
• To understand the future market competition in the Sialorrhea market.
1. Key Insights
2. Sialorrhea Market Overview at a Glance
- 2.1. Market Share (%) of Sialorrhea in 2017 – 7MM
- 2.2. Market Share (%) of Sialorrhea in 2028 – 7MM
3. Disease Background and Overview
- 3.1. Introduction
- 3.2. Classification of Sialorrhea
- 3.3. Etiology of Sialorrhea
- 3.4. Sialorrhea associated risk factors
- 3.5. Physiology of salivary function
- 3.6. Pathophysiology of Sialorrhea
- 3.7. Clinical Features and Possible Complications of Sialorrhea
- 3.8. Assessment of Sialorrhea
4. Epidemiology and Patient Population
- 4.1. Key Findings
- 4.2. Total Cases of Sialorrhea in 7MM
5. Country Wise-Epidemiology
- 5.1. United States
- 5.1.1. Assumptions and Rationale
- 5.1.2. Epidemiology of Sialorrhea Associated Etiologies in the United States
- 5.1.3. Occurrence of Sialorrhea in the United States
- 5.1.4. Occurrence of Chronic Sialorrhea in the United States
- 5.2. EU-5
- 5.2.1. Assumptions and Rationale
- 5.2.2. Germany
- 5.2.3. France
- 5.2.4. Italy
- 5.2.5. Spain
- 5.2.6. United Kingdom
- 5.3. Japan
- 5.3.1. Assumptions and Rationale
- 5.3.2. Epidemiology of Sialorrhea Associated Etiologies in Japan
- 5.3.3. Occurrence of Sialorrhea in Japan
- 5.3.4. Occurrence of Chronic Sialorrhea in Japan
6. Treatment and Management
- 6.1. Treatment for Children
- 6.2. Treatment for Clozapine-induced Sialorrhea
- 6.3. Treatment of Sialorrhea in Parkinson’s disease
- 6.4. Patient Journey
7. Unmet Needs
8. Case Studies
- 8.1. Scopolamine Ointment for Clozapine-Associated Sialorrhea: A Case Report
- 8.2. Surgical management of Chronic Sialorrhea in pediatric patients: 10- year experience from one tertiary care institution
9. Marketed Products
- 9.1. Cuvposa: Merz Pharmaceuticals
- 9.1.1. Product Description
- 9.1.2. Product Development Activities
- 9.1.3. Clinical Development
- 9.1.4. Safety and Efficacy
- 9.1.5. Product Profile
- 9.2. Sialanar (glycopyrronium bromide): Proveca Pharma Ltd
- 9.2.1. Product Description
- 9.2.2. Product Development Activities
- 9.2.3. Clinical Development
- 9.2.4. Product Profile
10. Emerging Drugs
- 10.1. Key Cross Competition
- 10.2. Myobloc: US WorldMeds
- 10.2.1. Product Description
- 10.2.2. Product Development Activities
- 10.2.3. Clinical Development
- 10.2.4. Safety and Efficacy
- 10.2.5. Product Profile
- 10.3. Xeomin (incobotulinumtoxinA): Merz Pharma
- 10.3.1. Product Description
- 10.3.2. Product Development Activities
- 10.3.3. Clinical Development
- 10.3.4. Safety and Efficacy
- 10.3.5. Product Profile
- 10.4. NH004: NeuroHealing Pharmaceuticals
- 10.4.1. Product Description
- 10.4.2. Product Development Activities
- 10.4.3. Clinical Development
- 10.4.4. Safety and Efficacy
- 10.4.5. Product Profile
11. Other Clinical Candidates
- 11.1. OP-014 (clonidine/oxybutynin): Orient Pharma
- 11.1.1. Product Description
- 11.1.2. Clinical Development
- 11.1.3. Product Profile
- 11.2. NT0502: Neos Therapeutics
- 11.2.1. Product Description
- 11.2.2. Product Development Activities
- 11.2.3. Product Profile
12. Off label Drugs
13. Sialorrhea: 7 Major Market Analysis
- 13.1. Key Findings
- 13.2. Market Size of Sialorrhea in 7MM
- 13.3. Market Outlook: 7MM
14. The United States Market Outlook
- 14.1. United States Market Size
- 14.1.1. Total Market size of Sialorrhea
- 14.1.2. Market Size by Therapies
15. EU-5 Countries: Market Outlook
- 15.1. Germany
- 15.1.1. Total Market size of Sialorrhea in Germany
- 15.1.2. Market Size by Therapies
- 15.2. France
- 15.2.1. Total Market Size of Sialorrhea
- 15.2.2. Market Size by Therapies
- 15.3. Italy
- 15.3.1. Total Market Size of Sialorrhea
- 15.3.2. Market Size by Therapies
- 15.4. Spain
- 15.4.1. Total Market Size of Sialorrhea
- 15.4.2. Market Size by Therapies
- 15.5. The United Kingdom
- 15.5.1. Total Market Size of Sialorrhea
- 15.5.2. Market Size by Therapies
16. Japan: Market Outlook
- 16.1. Japan Market Size
- 16.2. Total Market Size of Sialorrhea
- 16.3. Market Size by Therapies
17. Market Drivers
18. Market Barriers
19. Appendix
- 19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
1. Key Insights
2. Sialorrhea Market Overview at a Glance
- 2.1. Market Share (%) of Sialorrhea in 2017 – 7MM
- 2.2. Market Share (%) of Sialorrhea in 2028 – 7MM
3. Disease Background and Overview
- 3.1. Introduction
- 3.2. Classification of Sialorrhea
- 3.3. Etiology of Sialorrhea
- 3.4. Sialorrhea associated risk factors
- 3.5. Physiology of salivary function
- 3.6. Pathophysiology of Sialorrhea
- 3.7. Clinical Features and Possible Complications of Sialorrhea
- 3.8. Assessment of Sialorrhea
4. Epidemiology and Patient Population
- 4.1. Key Findings
- 4.2. Total Cases of Sialorrhea in 7MM
5. Country Wise-Epidemiology
- 5.1. United States
- 5.1.1. Assumptions and Rationale
- 5.1.2. Epidemiology of Sialorrhea Associated Etiologies in the United States
- 5.1.3. Occurrence of Sialorrhea in the United States
- 5.1.4. Occurrence of Chronic Sialorrhea in the United States
- 5.2. EU-5
- 5.2.1. Assumptions and Rationale
- 5.2.2. Germany
- 5.2.3. France
- 5.2.4. Italy
- 5.2.5. Spain
- 5.2.6. United Kingdom
- 5.3. Japan
- 5.3.1. Assumptions and Rationale
- 5.3.2. Epidemiology of Sialorrhea Associated Etiologies in Japan
- 5.3.3. Occurrence of Sialorrhea in Japan
- 5.3.4. Occurrence of Chronic Sialorrhea in Japan
6. Treatment and Management
- 6.1. Treatment for Children
- 6.2. Treatment for Clozapine-induced Sialorrhea
- 6.3. Treatment of Sialorrhea in Parkinson’s disease
- 6.4. Patient Journey
7. Unmet Needs
8. Case Studies
- 8.1. Scopolamine Ointment for Clozapine-Associated Sialorrhea: A Case Report
- 8.2. Surgical management of Chronic Sialorrhea in pediatric patients: 10- year experience from one tertiary care institution
9. Marketed Products
- 9.1. Cuvposa: Merz Pharmaceuticals
- 9.1.1. Product Description
- 9.1.2. Product Development Activities
- 9.1.3. Clinical Development
- 9.1.4. Safety and Efficacy
- 9.1.5. Product Profile
- 9.2. Sialanar (glycopyrronium bromide): Proveca Pharma Ltd
- 9.2.1. Product Description
- 9.2.2. Product Development Activities
- 9.2.3. Clinical Development
- 9.2.4. Product Profile
10. Emerging Drugs
- 10.1. Key Cross Competition
- 10.2. Myobloc: US WorldMeds
- 10.2.1. Product Description
- 10.2.2. Product Development Activities
- 10.2.3. Clinical Development
- 10.2.4. Safety and Efficacy
- 10.2.5. Product Profile
- 10.3. Xeomin (incobotulinumtoxinA): Merz Pharma
- 10.3.1. Product Description
- 10.3.2. Product Development Activities
- 10.3.3. Clinical Development
- 10.3.4. Safety and Efficacy
- 10.3.5. Product Profile
- 10.4. NH004: NeuroHealing Pharmaceuticals
- 10.4.1. Product Description
- 10.4.2. Product Development Activities
- 10.4.3. Clinical Development
- 10.4.4. Safety and Efficacy
- 10.4.5. Product Profile
11. Other Clinical Candidates
- 11.1. OP-014 (clonidine/oxybutynin): Orient Pharma
- 11.1.1. Product Description
- 11.1.2. Clinical Development
- 11.1.3. Product Profile
- 11.2. NT0502: Neos Therapeutics
- 11.2.1. Product Description
- 11.2.2. Product Development Activities
- 11.2.3. Product Profile
12. Off label Drugs
13. Sialorrhea: 7 Major Market Analysis
- 13.1. Key Findings
- 13.2. Market Size of Sialorrhea in 7MM
- 13.3. Market Outlook: 7MM
14. The United States Market Outlook
- 14.1. United States Market Size
- 14.1.1. Total Market size of Sialorrhea
- 14.1.2. Market Size by Therapies
15. EU-5 Countries: Market Outlook
- 15.1. Germany
- 15.1.1. Total Market size of Sialorrhea in Germany
- 15.1.2. Market Size by Therapies
- 15.2. France
- 15.2.1. Total Market Size of Sialorrhea
- 15.2.2. Market Size by Therapies
- 15.3. Italy
- 15.3.1. Total Market Size of Sialorrhea
- 15.3.2. Market Size by Therapies
- 15.4. Spain
- 15.4.1. Total Market Size of Sialorrhea
- 15.4.2. Market Size by Therapies
- 15.5. The United Kingdom
- 15.5.1. Total Market Size of Sialorrhea
- 15.5.2. Market Size by Therapies
16. Japan: Market Outlook
- 16.1. Japan Market Size
- 16.2. Total Market Size of Sialorrhea
- 16.3. Market Size by Therapies
17. Market Drivers
18. Market Barriers
19. Appendix
- 19.1. Report Methodology
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight
Summary:
Get latest Market Research Reports on Sialorrhea. Industry analysis & Market Report on Sialorrhea is a syndicated market report, published as Sialorrhea- Market Insights, Epidemiology and Market Forecast-2028. It is complete Research Study and Industry Analysis of Sialorrhea market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
